Related Experiment Video

Updated: May 11, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Natalizumab and the development of extensive brain lesions in neuromyelitis optica

Maciej Juryńczyk, Krzysztof Zaleski, Krzysztof Selmaj

    Journal of Neurology
    |May 31, 2013
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
    10:50

    Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

    Published on: March 26, 2019

    Related Experiment Videos

    Last Updated: May 11, 2026

    Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
    09:29

    Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

    Published on: August 21, 2017

    Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
    10:50

    Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

    Published on: March 26, 2019

    Related Concept Videos

    Multiple Sclerosis l: Introduction01:19

    Multiple Sclerosis l: Introduction

    Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
    Encephalitis ll: Pathophysiology01:26

    Encephalitis ll: Pathophysiology

    Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

    Articles linked to this work by shared authors, journal, and citation graph.

    Unique expression pattern of circulating exosomal miRNA correlates with CNS pathology.

    Frontiers in immunology·2026

    Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

    Frontiers in immunology·2026

    Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study.

    Neurology and therapy·2026

    Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

    Lancet (London, England)·2026

    A new, glycoengineered form of anti-CD20 monoclonal antibody, in treatment of multiple sclerosis.

    Therapeutic advances in neurological disorders·2026

    Novel homozygous SYNE1 missense variant in late onset autosomal recessive cerebellar ataxia 1: a case report.

    Therapeutic advances in neurological disorders·2026

    Real-world neuropsychiatric safety profile of foslevodopa/foscarbidopa infusion in advanced Parkinson's disease.

    Journal of neurology·2026

    Stroke secondary to cancer-associated coagulopathy: a systematic review.

    Journal of neurology·2026

    Visual snow syndrome as a neuropsychiatric network disorder: clinical features, mechanisms, and therapeutic perspectives.

    Journal of neurology·2026

    Central nervous system manifestations in hereditary transthyretin amyloidosis: a cross-sectional study with 151 patients.

    Journal of neurology·2026

    Clinical trials in non-ambulatory people with progressive multiple sclerosis: can the nine hole peg test step up as primary outcome measure?

    Journal of neurology·2026

    Safety and efficacy of repeated intravenous thrombolysis within 3 months for acute ischemic stroke: a systematic review and individual-patient data meta-analysis.

    Journal of neurology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us